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genes. Cases were only resolved following treatment with nitroscanate or a compounded pyrantel/
praziquantel/oxantel product. Clinicians should be aware of this alarming development as treatment options
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Abstract. Dipylidium caninum is a cosmopolitan cestode infecting dogs, cats, and humans. Praziquantel is a highly
effective cestocidal drug and resistance in adult cestodes has not been reported. From2016 to 2018, a population of dogs
with cestode infections that could not be eliminated despite multiple treatments with praziquantel or epsiprantel was
identiﬁed. Cases of D. caninumwere clinically resistant to praziquantel and could not be resolved despite increasing the
dose, frequency, and duration of treatment. Resistant isolates were identiﬁed and characterized by sequencing the 28S,
12S, and voltage-gated calcium channel beta subunit genes. Cases were only resolved following treatment with nitro-
scanate or a compounded pyrantel/praziquantel/oxantel product. Clinicians should be aware of this alarming develop-
ment as treatment options for cestodes are limited in both human and veterinary medicine.
INTRODUCTION
Dipylidium caninum is a cestode parasite that commonly
infects dogs and cats.1 Deﬁnitive hosts become infected fol-
lowing ingestion of a metacestode in an arthropod in-
termediate host. Typical intermediate hosts are the ﬂeas
Ctenocephalides felis and Xenopsylla cheopis,2 or potentially
the liceTrichodectescanis3 andFelicola subrostratus.4Humans,
especially infants, can be deﬁnitive hosts for D. caninum fol-
lowing accidental ingestion of arthropods that contain the cys-
ticercoid metacestode.
In veterinary medicine, control of D. caninum involves
treating dogs and cats with praziquantel5 or epsiprantel6
alone, or in combination with other anthelmintics for broad-
spectrum coverage.7–10 Praziquantel is also used to treat
human D. caninum infections after parasitological identiﬁca-
tion of the cestode.11 In addition, control of ectoparasites
(ﬂeas and lice) aids in breaking the life cycle of the parasite and
in preventing transmission of the cestode to the vertebrate
host.12–14 In veterinarymedicine, control ofD.caninum ismore
often focused on eliminating ectoparasite intermediate hosts.
Praziquantel is an important drug for the control of platy-
helminth parasites. There are several reports of reduced pra-
ziquantel susceptibility and failed clearance of trematode
infections caused by Schistosomamansoni and Schistosoma
haematobium in endemic areas.15 To date, there havebeen no
reports of resistance to praziquantel in adult cestodes and
clinical efﬁcacy has been 100%.16 This report describes
clinical resistance to praziquantel in the zoonotic cestode
D. caninum.
MATERIALS AND METHODS
Casedescriptions. In theSummer of 2016, a veterinarian in
Iowa recovered several cestodes while performing physical
examination on a litter of puppies before issuing a certiﬁcate of
veterinary inspection thatwould allow for interstatemovement
of the dogs. These specimens were submitted to the De-
partment of Veterinary Pathology, Iowa State University for
identiﬁcation. At that time, the proglottids were identiﬁed as
D. caninum, based on gross morphological features and
characteristic egg packets expressed from the proglottids in
squash preparations. The laboratory conferred with the re-
ferring veterinarian and developed a plan for integrated para-
site control involving sanitation, use of praziquantel, and
application of multimodal ﬂea control.
Subsequently, between 2016 and 2017, the laboratory re-
ceived inquiries from veterinarians in four different states
(Colorado, Iowa, Michigan, and Minnesota) regarding ces-
todes that were refractory to praziquantel treatment at label
doses (³ 5 mg/kg). Four of the cases originated from the
population we examined in our initial study and onewas a dog
that originated in Florida and now resides in Iowa. The ﬁrst four
cases were young dogs, less than 2 years of age, whereas the
ﬁfth dog was middle-aged, approximately 5 years of age. All
referring veterinarians were administering adequate ﬂea con-
trol by administration of topical parasiticides and/or oral iso-
xazolines, and no ﬂeas or ﬂea dirt (digested blood indicating
infestation) were found on any of the dogs. All treatmentswere
administered by a veterinarian whenever possible.
Treatments. Case 1. Michigan (Pomeranian). The patient
was administered oral epsiprantel (5.5 mg/kg), injectable
praziquantel (5 mg/kg), oral praziquantel (10 mg/kg), and a
combination praziquantel/pyrantel/febantel product daily for
8 weeks. The patient continued to shed proglottids posttreat-
ment and was lost to follow-up after changing veterinarians.
Case 2. Colorado (Pomeranian). Before identiﬁcation of the
cestode, the patient received oral fenbendazole (50 mg/kg)
once daily for 5 days and oral praziquantel (10 mg/kg) once
daily for 2 days. At this time, oral heartworm prevention once
monthly (2.3mgmilbemycin oximewith 22.8mg praziquantel)
was started. Next, a course of oral praziquantel (10 mg/kg)
once weekly for 6 weeks was prescribed. The patient then
received oral praziquantel (10.8mg/kg), pyrantel (10.8mg/kg),
and febantel (54 mg/kg) once daily for 3 days. After no im-
provement, 2 weeks later, the dosages were increased to oral
praziquantel (20 mg/kg), pyrantel (20 mg/kg), and febantel
(108 mg/kg) once weekly for 2 weeks. With no improvement,
2 weeks later, an oral dose of nitroscanate (47 mg/kg) was
administered. Oral nitroscanate was administered again (84
mg/kg) 2 weeks after the initial dose. No clinical side effects
associated with the increased dose were noted and proglot-
tids were no longer observed.
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Case 3. Iowa (Pomeranian). The patient was administered
oral or injectable praziquantel (5 mg/Kg) at three veterinary
visits, followedbydouble doseor oral praziquantel (10mg/kg).
The patient was then administered weekly praziquantel (5 mg/
kg) for 6 weeks and daily praziquantel for 3 days. Following
treatment with a compounded pyrantel/praziquantel/oxantel
product daily for 3 days, proglottids were no longer observed.
Case 4. Minnesota (Pomeranian). The patient was admin-
istered oral and injectable praziquantel (5 mg/kg) at different
veterinary visits, and then weekly for 6 weeks, followed by
praziquantel (5mg/kg) daily for 2weeks. The dog continued to
shed proglottids intermittently for approximately 4–5 months
until the shedding spontaneously ceased.
Case 5. Iowa (Jack Russell Terrier). The patient was admin-
istered oral epsiprantel (5.5 mg/kg), oral epsiprantel (5.5mg/kg)
weekly for 7 weeks, injectable praziquantel (5 mg/kg) and oral
epsiprantel (5.5 mg/kg) weekly for 4 weeks, epsiprantel orally
followed by epsiprantel every 3 days for 12 days, and epsi-
prantel (11 mg/kg) and injectable praziquantel (10mg/kg) every
3days for12days, andcontinued toshedproglottids.Following
treatment with a compounded pyrantel/praziquantel/oxantel
product daily for 5 days, proglottids were no longer observed.
Molecular characterization. Proglottids were received
from three of the ﬁve cases (Cases 1, 2, and 5) for identiﬁcation
and analysis. Proglottids were preserved in ethanol and ex-
amined for gross morphological features. Molecular charac-
terization was also performed. Cestode DNA was extracted
using the DNeasy blood and tissue kit (Qiagen, Valencia, CA).
A fragment of the nuclear rRNA encoding 28S gene that
encodes the large ribosomal subunit was ampliﬁed and se-
quenced using the primers 59-GCATGCAAGTCAAAGGGT
CCTACG-39 and 59-CACATTCAACGCCCGACTCCTGTAG-
39.17 A fragment of themitochondrial rRNAencoding12Sgene
was ampliﬁed and sequenced using the primers 59-TTAA
GATATATGTGGTACAGGATTAGATACCC-39 and 59-AACC
GAGGGTGACGGGCGGTGTGTACC-39.18 Nucleotide basic
local alignment search tool (BLAST) wascarriedout against the
nonredundant nucleotide collection of GenBank, andmaximum
likelihood (ML) trees forbothgeneswereconstructed inMega719
with thebest-ﬁtmodelsdeterminedusingBayesian information
criterion calculations in jmodeltest 2.1.10.20
In addition, a fragment of the voltage-gated calciumchannel
beta subunit was ampliﬁed using the degenerate primers 59-
AAYAAYGAYGGTGGAT-39 and 59-GCYTTYTGCATCATRTC-
39,21 cloned, and sequenced. BlastX search tool was used
to compare the translated protein against the nonredundant
protein sequence database on GenBank, and a neighbor-
joining tree with the maximum composite likelihood model
was constructed using Mega7.19
RESULTS
Gravidproglottidswere approximately 1 cm in length,white,
and tapered slightly at each end to give a “cucumber seed”
appearance. Genital pores were located laterally. When
crushed between glass slides, egg packets could be
expressed from the proglottids, and measured 120–200 μm.
Many hexacanth eggs in clusters were embedded in the egg
capsule (Figure 1). Thus, all submissions were typical pro-
glottids of the D. caninum.
BLASTn analysis of a 337 fragment of the mitochondrial
12S sequences revealed 100% identity between the three
sequences, 100% identity with some isolates of D. caninum
(AB732959 and AB031362), and 88–89% identity with other
isolates (KY751955, KF202097, and L49460). BLASTn anal-
ysis of a 632-bp fragment of the nuclear 28S sequences
revealed 100% identity between them, 99.4% identity with
D. caninum (AF023120), and 94–95% identity with other iso-
lates (MG575740, MG575741, MG575742, MG575743, and
KY751956). 12S and 28S sequences from this study were
deposited in GenBank (accession numbers MH182479–
MH182481 and MH182476–MH182478, respectively).
The best-ﬁt models for the 12S and 28S ML trees were
determined to be Hasegawa–Kishino–Yano with gamma dis-
tribution (HSY + G) and equal frequency Tamura-Nei models,
respectively. Echinococcus multilocularis 12S (AB018440)
and Raillietina australis 28S (AF286914) were used as out-
groups. In both ML trees, two distinct clades were distin-
guishable, and all Dipylidium isolates from the present study
clustered within a single clade in both trees (Figures 2 and 3).
A 713-bp fragment of the voltage-gated calcium channel
beta subunit was cloned from genomic DNA, spanning an
exon–intron boundary of the gene. Voltage-gated calcium
channel sequences from this studyweredeposited inGenBank
(accession numbers MH189719–MH189720). BLASTx anal-
ysis revealed that the sequence encodes a part of the Beta
interacting domain (BID) of the voltage-dependent L-type
calcium channel beta-1 subunit, and included the Src ho-
mology 3domain, typical of theBID. The translated amino acid
sequence had the following identities with various voltage-
gated calcium channel beta subunits: 81%with Taenia solium
(AAV31726); 89% identity each with Echinococcus granulosus
(EUB60654 and CDS23505), E. multilocularis (CDS39653),
and Hymenolepis microstoma (CDS33662); and 82% identity
with Schistosoma japonicum (AAX28365) and S. mansoni
(AAQ19186). In the neighbor-joining tree of voltage-gated
calcium channel beta subunit sequences, the cloned frag-
ments from Dipylidium cluster with sequences from Hyme-
nolepis nana (Figure 4).
DISCUSSION
A number of cestodes parasitize human deﬁnitive hosts,
including selected species of Diphyllobothrium, Spirometra,
Taenia,Hymenolepis, andDipylidium.22Dipylidium caninum is
most commonly found in dogs and cats, but can infect hu-
mans if they ingest arthropods containing the cysticercoid
metacestode. Generally, Dipylidium infections induce mild to
FIGURE 1. Egg capsules. Hexacanth embryos embedded in egg
capsulesseen in crushpreparationsof proglottids. Thisﬁgureappears
in color at www.ajtmh.org.
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no clinical signs in dogs and cats.When signs occur, theymay
include abdominal pain, vomiting/diarrhea, and may be ac-
companied by amild anal pruritus associated with proglottids
in the perianal area. In humans, D. caninum infections occur
occasionally, mainly in children who acquire the infection by
ingesting intermediate hosts such as ﬂeas. In this report, we
document D. caninum that is clinically resistant to prazi-
quantel, the mainstay of anti-cestode therapy.
A combination of classical parasitology and molecular
techniques was used to conclude that the infections were
caused by D. caninum. One drawback of this study was the
inability to establish the resistant clinical isolates in experi-
mentally infected laboratory animals to further study them.
Reliable experimentalDipylidium infection in dogs using a ﬂea
infestation model has only recently been established13,14 and
involves rearing of ﬂea larvae in classical ﬂea-breeding units
withD. caninum egg packets for up to 2 weeks to allow for the
development of the metacestode in the ﬂeas before ingestion
by dogs or cats.
In our investigation, noneof the ﬁve cases could be resolved
with label doses of praziquantel alone. Likewise, these infec-
tions could not be treated with epsiprantel, a closely related
isoquinolone. Attempts using higher doses and durations of
treatment also failed. Praziquantel has relatively low host
toxicity and no side effects were associated with extended
treatments. Often, reports of drug resistance in veterinary
parasites can be associated with poor client compliance
whereby medications are not given appropriately. In the pre-
sent cases, treatments were administered by a veterinarian
whenever possible. One of the infections was successfully
treated with nitroscanate, two were successfully treated with
a compounded pyrantel/praziquantel/oxantel product, one
FIGURE 2. Maximum likelihood tree—mitochondrial 12S gene. The evolutionary history was inferred by using the maximum likelihood method
based on theHasegawa–Kishino–Yanomodel with a discrete Gammadistribution tomodel evolutionary rate differences among sites. The analysis
involved nine nucleotide sequences and a total of 295 positions in the ﬁnal dataset. Evolutionary analyses were conducted in MEGA7.
FIGURE 3. Maximum likelihood tree—nuclear 28Sgene. The evolutionary historywas inferred by using themaximum likelihoodmethodbased on
theTamura–Neimodel. Theanalysis involved10nucleotidesequences.Therewerea total of 580positions in theﬁnal dataset. Evolutionary analyses
were conducted in MEGA7.
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spontaneously ceased shedding proglottids after several
months of treatment, and one was lost to follow-up. It is un-
clear why the compounded product was effective despite
multiple failures of praziquantel and epsiprantel. It is possible
that pyrantel acted synergistically, as there is evidence that it
may act against some cestodes of veterinary interest.23 An-
ecdotally, other dogs originating from the infected litter
spontaneously ceased sheddingproglottids followingmonths
of unsuccessful chemotherapy. It is possible that these ces-
todes were expelled following their natural lifetime, the dura-
tion of which is not well characterized.
The exactmechanismof praziquantel action is yet to be fully
elucidated, and new targets are being studied to fully account
for drug activity.24 One well-studied and widely accepted
target of praziquantel is the cestode voltage-gated calcium
channels.21 In our study, we cloned a partial sequence of the
beta subunit of the voltage-gated calcium channel from the
resistant cestodes, but analysis was constrained by the com-
plete lack of availability of genome sequences of D. caninum.
Future studies will assess the possibility that polymorphisms
in the voltage-gated calcium channel account for clinical pra-
ziquantel resistance.
Praziquantel is the drug of choice for cestode infections,25
and is the sole drug used on a large scale for human schis-
tosomiasis.26 In veterinary species, oral, topical, and inject-
able praziquantel formulations are available for use against
cestodes and trematodes.27 Despite the widespread use of
praziquantel in human and veterinary medicine, examples of
drug resistance in platyhelminthes are rare as compared with
reports of drug-resistant nematodes.28 These reports are
more common in hyperendemic areas and are potentially
associated with frequent exposure to the drug.29,30 Although
mass drug administration is common for control of veterinary
parasites, and nematode drug resistance has become a seri-
ousproblem, cestodedrug resistance is notwell documented.
This study is the ﬁrst to report praziquantel resistance in
D. caninum, a cestode with zoonotic importance. Future
studies with clinically resistant isolates to elucidate the exact
mechanism of resistance are necessary, along with epidemi-
ological studies to determine to determine the extent of the
resistance problem. Practitioners should be aware of the
presence of praziquantel-resistant D. caninum in the United
States.
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